Effect of low weekly doses of mifepristone on ovarian function and endometrial development.
The effect of a low dose of mifepristone (RU486) on ovarian and endometrial function was studied in 14 healthy women. The study included one control and two treatment cycles. During the treatment cycles, either 2.5 mg (n = 9) or 5 mg (n = 5) of mifepristone was administered once weekly. The concentration of ovarian steroids and luteinizing hormone (LH) in urine was measured daily, cortisol in blood once weekly and glycodelin (placental protein 14; PP14) at the time of menstruation. Ovarian function was monitored by vaginal ultrasound. An endometrial biopsy was taken in each cycle in the mid-luteal phase, based on self-measurement of the LH peak, or on cycle day 22 if no LH peak could be detected. In the evaluation of the results, the outcome of the enzyme immunoassay of LH was used to date the biopsy. Endometrial progesterone and oestrogen receptors and Dolichus biflorus agglutinin (DBA) lectin binding were measured. Ovulation was not inhibited by treatment with mifepristone, and an LH peak could be determined in all control and treatment cycles. However, in four subjects (one with the higher and three with the lower dose) the follicular phase was prolonged by 6-13 days. The duration of the luteal phase and the concentrations of pregnanediol and oestrone glucuronide were not affected by treatment. A dose of 5 mg, and to a lesser extent 2.5 mg, mifepristone once weekly caused desynchronization of endometrial development. Endometrial progesterone receptor, but not oestrogen receptor, concentration was significantly increased by the higher dose. A significant reduction in DBA-lectin binding and in serum glycodelin concentrations was also found. Thus, low doses of mifepristone do not inhibit ovulation but delay endometrial development and impair secretory activity. Whether these effects are sufficient to prevent implantation remains to be established.
Gemzell-Danielsson
K
K
Department of Woman and Child Health, Karolinska Hospital, Stockholm, Sweden.
Westlund
P
P
Johannisson
E
E
Swahn
M L
ML
Bygdeman
M
M
Seppälä
M
M
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004717:Endometrium / Q000187:drug effects* / Q000502:physiology; D005260:Female; D000071816:Glycodelin; D006023:Glycoproteins / Q000097:blood; D006651:Histocytochemistry; D006801:Humans; D007150:Immunohistochemistry; D037102:Lectins; D007986:Luteinizing Hormone / Q000097:blood; D008597:Menstrual Cycle / Q000187:drug effects; D015735:Mifepristone / Q000008:administration & dosage* / Q000627:therapeutic use; D006080:Ovarian Follicle / Q000187:drug effects; D010053:Ovary / Q000187:drug effects* / Q000502:physiology; D010060:Ovulation / Q000187:drug effects; D011257:Pregnancy Proteins / Q000097:blood; D012016:Reference Values
D000071816:Glycodelin; D006023:Glycoproteins; D037102:Lectins; C045246:PAEP protein, human; D011257:Pregnancy Proteins; D015735:Mifepristone; D007986:Luteinizing Hormone